



2013, Vol. 20, No. 1, pp. 25–28
10.5603/CJ.2013.0005
Copyright © 2013 Via Medica
ISSN 1897–5593
Address for correspondence: Dr. Mustafa Yildiz, MD, PhD, Prof. Cardiologist, Internal Medicine Specialist and Physiologist,
Bayar Cad Gülbahar Sok Emniyet Sitesi D6, Kozyatagi, Istanbul, Turkey, tel: +90 0216 459 78 00, telefax: +90 0216 459 63 21,
e-mail: mustafayilldiz@yahoo.com
Received: 15.09.2012 Accepted: 11.10.2012
Outcomes and effectiveness of bilateral percutaneous
transluminal renal artery stenting in patients
with critical bilateral renal artery stenosis
Mustafa Yildiz1, Suleyman Karakoyun1, Banu Sahin Yildiz2,
Alparslan Sahin3, Ibrahim Akin4
1Department of Cardiology, Kartal Kosuyolu Yüksek Ihtisas Educational and Research Hospital, Istanbul, Turkey
2Deparment of Internal Medicine, Dr Lütfi Kirdar Educational and Research Hospital, Istanbul, Turkey
3Department of Cardiology, Dr Sadi Konuk Educational and Research Hospital, Istanbul, Turkey
4Department of Cardiology, Rostock University Medical Faculty, Rostock, Germany
Abstract
Background: The aim of this study was to assess the effects of percutaneous bilateral renal
artery stenting in patients with atherosclerotic renal artery stenosis and in-hospital and
4 month outcome of the procedure, focusing on the changes in renal function and blood pressure.
Methods: Five consecutive patients (mean age: 64.8 ± 9.7 years, 1 women) with bilateral
renal artery stenoses underwent percutaneous interventions. We compared blood pressure,
number of oral antihypertensive medications, and renal function changes preprocedure and
postprocedure at 4 months follow-up.
Results: A total of 5 bilateral atherosclerotic renal artery stenosis patients underwent
percutaneous transluminal renal angioplasty and 10 stents were placed. Although systolic and
diastolic blood pressures were significantly decreased in follow-up period, glomerular filtration
rates were not significantly changed as compared with baseline data (p = 0.009, p = 0.008,
p = 1.00, respectively). Also, the number of oral antihypertensive medications were significantly
decreased at follow-up period (p = 0.03).
Conclusions: Bilateral renal artery stenting provides a beneficial outcome such as
stabilization of renal functions, significant improvement in blood pressure control and
reduction in the number of oral antihypertensive medications at follow-up. (Cardiol J 2013;
20, 1: 25–28)
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Introduction
Percutaneous transluminal renal interventions
including angioplasty and stenting are important
methods for treatment of atherosclerotic renal ar-
tery stenoses [1]. However, as the procedure be-
came broadly applied from the beginning conflict-
ing results emerged. Although some patients
showed major benefit after percutaneous renal in-
terventions, others experienced further deteriora-
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tion of renal function [2]. Today it is acknowledged
that atherosclerotic renal artery stenoses is a com-
plex clinical condition that ranges from asymptoma-
tic disease to high grade bilateral disease compli-
cated by progressive renal failure, recurrent pulmo-
nary edema, and severe hypertension. Current
indications for renal interventions have been partly
guided by the Angioplasty and STenting for Renal
Artery Lesions (ASTRAL) study [3] that has shown
this therapy makes little impact upon major out-
comes. Also, Chrysochou et al. [4] showed that sub-
groups including acute flash pulmonary edema and
acute kidney injury might benefit from intervention.
But, this conditions are a non-evidenced-based indi-
cation (Class I, Level of Evidence B) according to the
American College of Cardiology/American Heart
Association guidelines [5]. The aim of this study was
to assess the effects of percutaneous bilateral renal
artery stenting in patients with atherosclerotic re-
nal artery stenosis and in-hospital and 4 month out-
come of the procedure, focusing on the changes in
renal function and blood pressure.
Methods
Patients
Five consecutive patients (mean age: 64.8 ±
± 9.7 years, 1 women) with bilateral renal artery
stenoses underwent percutaneous interventions.
Three patients was admitted with chest pain and
drug resistant hypertension [6]. Also, 2 patients was
admitted hypertension and pulmonary edema. All
patients were diagnosed with luminal narrowing
≥ 70% by renal Doppler ultrasonography or com-
puted tomography before intervention. All subjects
gave their consent for inclusion in the study. The
investigation conforms with the principles outlined
in the Decleration of Helsinki. All the patients was
treated at the time of examination with minimum
3 antihypertensive drugs such as angiotensin rece-
ptor blockers, angiotensin-converting-enzyme in-
hibitors, nitrates, diuretics, alpha-blockers, beta-
-blockers and calcium channel blockers. The blood
pressure was measured, using a mercury sphygmo-
manometer with a cuff appropriate to the arm circu-
mference (Korotkoff phase I for systolic blood pres-
sure and V for diastolic blood pressure). Blood pres-
sure measurements were performed twice for each
subject and their mean was used for statistical ana-
lysis. Estimated glomerular filtration rate was cal-
culated using the Cockcroft-Gault formula [7]. The
patients were followed for 4 months. Baseline pa-
tient demographics and procedural data was pre-
sented in Table 1.








Coronary artery disease 3 (1 F)
Prior coronary bypass surgery 2 (1 F) PCI
and/or PCI
Previous smoker 1 (M)
Number of drugs-prestenting 3.40 ± 0.54
Number of drugs-poststenting 1.40 ± 0.54
Normal sinus rhythm 5
Ejection fraction (%) 62.40 ± 3.71
LVH and diastolic dysfunction 5
Systolic blood pressure [mm Hg]:
Preprocedural 178.00 ± 16.43
Postprocedural 142.00 ± 16.41
4 months 132.00 ± 8.36
Distolic blood pressure [mm Hg]:
Preprocedural 97.00 ± 8.35
Postprocedural 84.00 ± 5.47
4 months 76.00 ± 5.45
Glomerular filtration rate [ml/min]:
Preprocedural 30.38 ± 7.63
Postprocedural 30.27 ± 8.47
4 months 29.96 ± 7.16
Leukocytes [/mL] 7.56 ± 2.09
Hemoglobin [g/dL] 11.34 ± 0.39
Platelets [/mL] 322.00 ± 91.23
Sodium [mEq/L] 139.80 ± 2.38
Potassium [mEq/L] 4.38 ± 0.68
Choloride [mmol/L] 106.00 ± 3.16
Albumin [mg/dL] 3.96 ± 0.43
Sedimentation [mm/h] 22.00 ± 5.19
Brain natriuretic peptide [pg/mL] 341.00 ± 304.05
Glucose [mg/dL] 103.00 ± 10.83
Low-density lipoprotein [mg/dL] 114.20 ± 31.15
High-density lipoprotein [mg/dL] 34.18 ± 10.29
Cholesterol [mg/dL] 200.20 ± 43.92
Trygliceride [mg/dL] 193.80 ± 27.45
Right renal artery (14.0 ± 1.22)
stent size [cm] × (6.20 ± 0.83)
Left renal artery (15.02 ± 2.12)
stent size [cm] × (6.40 ± 0.54)
Postdilatation baloon 8.80 ± 1.30
pressure [atm]
M — male; F — female; PCI — percutaneous coronary interventions;
LVH — left ventricular hypertrophy
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Percutaneous technique
Femoral arterial puncture was performed in all
patients, and all procedures were performed
through a 6–8 F sheath introducer, with a renal ar-
tery guiding catheter introduced via a 0.36-mm or
0.46-mm guide wire. The guide wire was passed
through the stenosis and a balloon-expandable stent
was placed via the guide wire (Fig. 1A–C). For treat-
ment of ostial stenoses, the stent was positioned
so that 1 to 2 mm protruded into the aortic lumen,
ensuring complete coverage of the aortic plaque. An
intervention was considered technically successful
if the residual stenosis was < 30%. Antiplatelet
therapy was started at least 1 day before interven-
tion and routinely consisted of 75 mg of clopidogrel
daily for 3 months and 100 mg of aspirin indefinite-
ly. Immediately before the intervention, we admin-
istered a bolus dose of 5000 IU of heparin.
Statistical analysis
Statistics were obtained using the ready-to-use
programme of SPSS version 8.0. All the values were
expressed as mean ± standard deviation. The ob-
tained results for systolic blood pressure, diastolic
blood pressure and glomerular filtration rates were
assessed by non-parametrik Friedman test. Num-
ber of drugs use for hypertension was assessed by
non-parametrik Wilcoxon signed ranks test. The
significance level was set at a value of p < 0.05.
Results
A total of 5 bilateral atherosclerotic renal ar-
tery stenosis patients underwent percutaneous
transluminal renal angioplasty and 10 stents were
placed (Table 1). There were not any complication
during interventional procedure. The findings of
preprocedural, postprocedural and 4 months later
were presented in Table 1. Although systolic and
diastolic blood pressures were significantly de-
creased at follow-up period, glomerular filtration
rates were not significantly changed as compared
with baseline data (p = 0.009, p = 0.008, p = 1.00,
respectively). Also, the number of oral antihyper-
tensive medications were significantly decreased at
follow-up period (p = 0.03).
Discussion
Atherosclerotic renal artery stenosis may be
associated with renovascular hypertension, in-
creased cardiovascular morbidity and mortality [2].
Patients with bilateral critical atherosclerotic renal
artery stenosis are at increased risk for hyperten-
sion and acute pulmonary edema [4]. Resistant hy-
pertension, is defined as blood pressure that re-
mains above goal in spite of the concurrent use of
three antihypertensive agents of different classes
[6], and acute pulmonary edema are accepted as
1 of the few indications for consideration of renal
artery revascularization [4, 8, 9]. However, this is
Class I, Level of Evidence B indications according
to the American College of Cardiology/American
Heart Association guidelines [5]. Atherosclerotic
renal artery stenosis are usually located in the re-
nal artery ostium, and many are extensions of cal-
cified aortic plaque. Although, these tight and cal-
cified lesions tend to rebound to their original
shape with balloon angioplasty alone [10], we used
balloon expandable stent that provides the additional
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force needed to permanently disrupt the lesions,
leading to a longer-lasting result [10]. This study
showed that percutaneous transluminal bilateral
renal artery stenting significantly reduced both
systolic and diastolic blood pressure at postproce-
dural period compared to baseline. Also, it de-
monstrated a significant improvement in blood
pressure control and reduction in the number of
oral antihypertensive medications at follow-up
period, as in other studies [4, 10].
Although serum creatinine levels may be al-
tered by some factors such as body muscle mass
and age, we used glomerular filtration rate using the
Cockcroft-Gault formula [7], which is a more sen-
sitive marker of renal function. Revascularization
of the renal artery with stenting to preserve renal
function is based on the assumption that ischemia
contributes to renal insufficiency and that correc-
tion of the stenosis and restoration of renal perfu-
sion will stabilize, as in our study, or improve renal
function [10]. Considering the dialysis patients who
reduces life expectancy and quality of life, any sta-
bilization of renal function should be regarded as
a beneficial outcome.
Limitations of the study
These conclusions may not extand to the great
population, therefore; the results of this study will
need confirmation in larger studies.
Conclusions
In conclusion, the findings of our study indicate
that bilateral renal artery stenting provides a bene-
ficial outcome such as stabilization of renal func-
tions, significant improvement in blood pressure
control and reduction in the number of oral antihy-
pertensive medications at follow-up.
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